Published Friday May 22, 2026 post-market. Results data from official company filings and verified news sources. Not investment advice. Not SEBI registered. Full disclaimer.
1. Sun Pharma Q4 FY26 — PAT +26%, US Crosses $1 Billion, Dividend ₹16 Total
India formulations +14.8% (CVD, CNS, Gastro, Ortho). Gross margin improved to 80.8%. US revenue $459 million — marginal dip. R&D at 6.7% of sales. US Innovative Medicines crossed $1 billion. Organon acquisition announced at $11.75 billion. FY26 full year revenue ₹58,220 Cr (+11.9%), PAT ₹11,479 Cr (+5%). Kirti Ganorkar, MD: “Our US Innovative Medicines business has surpassed $1 billion in revenues. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation.”
2. Eicher Motors Q4 FY26 — Royal Enfield Momentum Intact: PAT +12%, Dividend ₹82
Full year FY26 revenue ₹23,407.56 crore. Group consolidated PAT ₹5,515.23 crore. ₹82 dividend is 17% increase over FY25’s ₹70 — a strong capital return signal. VECV (commercial vehicles) continues to contribute. Exceptional item: ₹55.45 crore provisioned for Labour Codes impact.
3. Hindalco Q4 FY26 — Revenue Surges 17% QoQ to ₹78,133 Cr; Read the Base Effect Carefully
Important: The −50.83% YoY PAT decline is against Q4 FY25 which included extraordinary Novelis gains during the aluminium price spike. Sequential PAT grew 26.74%. Revenue +20.38% YoY is genuine. Board approved QIP up to ₹5,000 crore — growth capital signal. India aluminium upstream and copper businesses performing well.
4. Colgate-Palmolive India Q4 FY26 — Revenue Beats Estimates, Dividend ₹48 Total FY26
Revenue of ₹1,583 crore beat sales estimates (range ₹1,500–1,580 crore). PAT of ₹353 crore is marginally lower than ₹355 crore last year — affected by GST-related inverted duty structure charges and higher interest income on tax refunds in the base year. QoQ, PAT rose 9.1% from ₹323.9 crore. FY26 full year net sales ₹5,984 crore. Growth was broad-based across portfolio, supported by premiumisation and domestic demand. AGM scheduled July 29, 2026. Total FY26 dividend of ₹48/share is a significant income investor positive.
5. NTPC Green Energy Q4 FY26 — Revenue Soars but Profit Falls 16%; ₹5,000 Cr Fundraise Approved
NTPC Green Energy’s PAT fell approximately 16% YoY against a very high base — Q4 FY25 PAT was ₹233.21 crore, a 188% jump that year. The profit decline despite surging revenue reflects higher finance costs as NTPC Green aggressively expanded its renewable capacity by 5,488 MW. The board approved raising up to ₹5,000 crore via bonds/NCDs in FY26-27 — capital to fund the next wave of renewable capacity. No dividend declared for Q4 FY26. This is a growth-investment story, not an income story — the metric that matters is capacity addition and revenue trajectory, not near-term PAT. CMP around ₹105.6 at market open, 52-week high ₹119.95 (April 27, 2026).
6. Torrent Pharma Q4 FY26 — Revenue +42% on JBCP, but PAT Falls 22% on One-Time Charge
Revenue surged 41.8% YoY to ₹4,197 crore primarily because JB Chemicals (JBCP) acquisition is now consolidated following Torrent’s ₹11,920 crore acquisition of a 46.4% controlling stake in June 2025. PAT declined 21.9% weighed by higher acquisition financing costs and a ₹66 crore one-time charge. Investor conference call at 6:30 PM IST — management guidance on JBCP synergy timeline is the key variable. The revenue growth is structural; the PAT pressure is transitional.
7. Star Cement Q4 FY26 — Clean +20% Growth; Dividend ₹3.60
Star Cement delivered a clean quarter — no one-time charges, no base effect distortions, no acquisition noise. Revenue +11.54%, PAT +20.24%, operating leverage working. Northeast India cement demand holds firm. Dividend ₹3.60/share, record date July 24. Source: Upstox Q4 live.
Full Results Table — All Major Companies May 22
| Company | Q4 PAT | YoY | Revenue | Dividend | Verdict |
|---|---|---|---|---|---|
| Sun Pharma | ₹2,714 Cr | +26.2% | ₹14,560 Cr (+13.6%) | ₹16 total FY26 | ✅ Beat |
| Eicher Motors | ₹1,519.95 Cr | +11.58% | ₹6,080 Cr (+16%) | ₹82/share | ✅ Solid |
| Colgate | ₹353.3 Cr | Flat | ₹1,583 Cr (+9%) | ₹48 total FY26 | ✅ Rev beat |
| Hindalco | ₹2,597 Cr | +27% QoQ | ₹78,133 Cr (+17% QoQ) | ₹5 (July 10) | 🟡 QoQ good |
| NTPC Green | ~₹196 Cr | −16% | Rev soared | None | ⚠️ Growth capex |
| Torrent Pharma | ₹389 Cr | −21.9% | ₹4,197 Cr (+41.8%) | — | ⚠️ One-time |
| Star Cement | ₹148.09 Cr | +20.24% | ₹1,173.55 Cr (+11.54%) | ₹3.60 (July 24) | ✅ Steady |
| Info Edge (Naukri) | ₹565.79 Cr | +22.1% | ₹869 Cr (+20.75%) | ₹3.60 (July 24) | ✅ Strong |
Source: Upstox Q4 live, BusinessToday, FreePressJournal, Screener.in, InvestyWise. Not investment advice.
The Analyst’s Read — What Today’s Results Tell You for Monday
Friday May 22’s results season tells a consistent story: domestic consumption-driven businesses (Sun Pharma India +14.8%, Eicher Motors +16%, Colgate +9%) are delivering clean, reliable growth. Sun Pharma and Eicher both beat estimates. Colgate beat sales estimates despite slightly flat PAT. The total FY26 dividend story — Sun Pharma ₹16, Colgate ₹48, Eicher ₹82 — reinforces management confidence in cash generation across sectors.
NTPC Green’s 16% PAT fall needs to be read in context: the company is aggressively building capacity (5,488 MW added) and approved ₹5,000 crore in fresh borrowings. This is a growth-investment phase, not a decline. The falling profit is a consequence of higher finance costs from capital deployment — the revenue trajectory and capacity numbers are the right metrics. Torrent Pharma’s JBCP story is similar — revenue inorganic growth is real, but the market will wait for Q1 FY27 numbers to see organic margin recovery.
For Monday’s trading: Sun Pharma’s ₹5 final dividend (record date to be announced) will attract income investors who missed Thursday’s ITC ₹8 dividend. Colgate at ₹48 total FY26 dividend is exceptional yield for an FMCG name. Both could see follow-through buying Monday morning. NTPC Green will likely be range-bound — the ₹5,000 crore fundraise is positive long-term but means equity dilution risk. Not investment advice.
Frequently Asked Questions
What were Sun Pharma Q4 FY26 results?
PAT ₹2,714 crore (+26.2% YoY). Revenue ₹14,560 crore (+13.6%). EBITDA margin 27.1%. Final dividend ₹5/share. Total FY26 dividend ₹16/share. US Innovative Medicines crossed $1 billion. Official: sunpharma.com.
What were Colgate Q4 FY26 results and dividend?
Revenue ₹1,583 crore (+9% — beat estimates). PAT ₹353.3 crore (flat). Second interim dividend ₹24/share declared. Total FY26 dividend ₹48/share. FY26 net sales ₹5,984 crore. AGM July 29. Official: colgate.co.in.
What were NTPC Green Energy Q4 FY26 results?
PAT fell approximately 16% YoY (~₹196 crore vs ₹233.21 crore in Q4 FY25) — higher finance costs from capacity investment. Revenue soared on 5,488 MW capacity addition. No dividend. Board approved raising ₹5,000 crore via bonds/NCDs for FY26-27. Official: ngel.in.
What were Eicher Motors Q4 FY26 results?
PAT ₹1,519.95 crore (+11.58% YoY). Revenue ₹6,080 crore (+16%). Dividend ₹82/share. Full year revenue ₹23,407 crore. Official: eichermotors.com.
Data from official company BSE/NSE filings, BusinessToday, FreePressJournal, Upstox Q4 live blog, Screener.in, ScanX, InvestyWise. Published May 22, 2026 post-market. Not SEBI registered. Not investment advice. See more Quarterly Results →
Leave a Reply